Stock Analysis
- Hong Kong
- /
- Life Sciences
- /
- SEHK:1873
Viva Biotech Holdings Full Year 2023 Earnings: CN¥0.06 loss per share (vs CN¥0.28 loss in FY 2022)
Viva Biotech Holdings (HKG:1873) Full Year 2023 Results
Key Financial Results
- Revenue: CN¥2.16b (down 9.4% from FY 2022).
- Net loss: CN¥116.1m (loss narrowed by 78% from FY 2022).
- CN¥0.06 loss per share (improved from CN¥0.28 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Viva Biotech Holdings shares are up 22% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 3 warning signs for Viva Biotech Holdings (1 can't be ignored!) that you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Viva Biotech Holdings is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:1873
Viva Biotech Holdings
An investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide.
Excellent balance sheet and good value.